Johnson & Johnson announced on Monday, September 21, 2026 that the European Commission granted marketing authorization for ICOTYDE (icotrokinra) for adults and adolescents aged 12 and older weighing at least 40 kg with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. J&J calls icotrokinra the first targeted oral peptide that precisely blocks the IL-23 receptor; it was jointly discovered and is being developed under J&J's license and collaboration agreement with Protagonist Therapeutics. The approval rests on the ICONIC program of four Phase 3 studies in about 2,500 patients (ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1 and 2). In the head-to-head studies, about 70% of patients on icotrokinra reached clear or almost clear skin (IGA 0/1) and 55% reached PASI 90 at week 16. Patients take one pill once daily with water on waking, at least 30 minutes before eating.
Takeda (NYSE: TAK) and Protagonist Therapeutics (NASDAQ: PTGX) announced Friday August 28, 2026 FDA approval of Mimrylo (rusfertide, a first-in-class subcutaneous synthetic hepcidin mimetic peptide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a rare BCR-ABL-negative myeloproliferative neoplasm in which uncontrolled red blood cell production drives increased thrombotic risk. Approval was based on the Phase 3 VERIFY trial (n=293) in which 76.9% of patients on rusfertide plus standard of care were phlebotomy-free through Week 32 versus 32.9% on placebo plus standard of care, with statistically significant improvements in hematocrit control and patient-reported fatigue and symptom burden. Adverse events were generally low-grade and included localized injection-site reactions (55.9%), anemia (15.9%), and fatigue (15.2%). Mimrylo will be commercialized by Takeda under the 2024 worldwide license and collaboration agreement with Protagonist and will ship within 48 hours. Jefferies analysts project peak sales potential of $2 billion. The mechanism (mimicking the natural iron-regulator hepcidin to constrain iron availability for erythropoiesis) is the first commercial validation of the hepcidin mimetic peptide class after more than a decade of academic development.
Protagonist Therapeutics (NASDAQ: PTGX) disclosed Friday August 28, 2026 that the Mimrylo FDA approval triggers $275 million in payments from Takeda, consisting of a $200 million opt-out fee (representing Protagonist's decision not to co-commercialize) and a separate $75 million approval milestone. The company retains additional undisclosed milestones and tiered royalties on rusfertide sales under the January 2024 worldwide license and collaboration agreement. Protagonist's platform-derived pipeline extends beyond rusfertide to include icotrokinra (an oral IL-23 receptor antagonist peptide licensed to Janssen, with a broad autoimmune-disease Phase 3 program) plus additional preclinical peptide programs across metabolic, inflammatory, and hematologic indications. The company's stock is expected to be one of the notable peptide-focused public-market performers of 2026 as rusfertide commercial ramp and icotrokinra Phase 3 readouts advance.